Selective drug delivery to bone using acidic oligopeptides

Editorial Manager(tm) for Journal of Bone and Mineral Metabolism
Manuscript Draft

Manuscript Number:

Title: Selective drug targeting to bone using acidic oligopeptides

Article Type: Review Article

Corresponding Author: Professor Ken-ichi Miyamoto, Ph.D.

Corresponding Author's Institution: Kanazawa University Hospital

First Author: Ken-ichi Miyamoto, Ph.D.

Order of Authors: Ken-ichi Miyamoto, Ph.D.

Abstract: Hard tissues, such as bone and teeth, consist of hydroxyapatite (HAP), collagenous proteins and noncollagenous proteins. Osteopontin and bone sialoprotein are two major noncollagenous proteins in bone and have many L-Asp and L-Glu repetitive sequences, respectively, as possible hydroxyapatite (HAP)-binding sites. Fluorescence-labeled acidic amino acid (L-Asp or L-Glu) homopeptides containing six or more residues bound strongly to HAP and were selectively delivered to and retained in bone after systemic administration. This result stimulated the development of bone-targeting drugs by tagging with acidic oligopeptides. Three model drugs, estradiol, quinolone antibiotics and tissue-nonspecific alkaline phosphatase (TNSALP), tagged with aspartic acid hexapeptide were examined the clinical feasibility of the acidic oligopeptide strategy for selective drug delivery to bone.

In vivo experiments confirmed the long acting effects of L-Asp hexapeptide-tagged estradiol and levofloxacin on animal models of osteoporosis and osteomyelitis, respectively, although there was loss of in vitro bioactivity, suggesting that the acidic hexapeptide was removed by hydrolysis in the body after delivery to bone. The adverse effect of estradiol on the uterus was greatly reduced by conjugation to the hexapeptide. The L-Asp hexapeptide-tagged TNSALP has the enzyme activity similar to untagged enzyme and was selectively delivered to bone and retained for long time in comparison with the untagged enzyme. These results support the usefulness of acidic oligopeptides as bone-targeting carriers for therapeutic agents.

Review

Selective drug targeting to bone using acidic oligopeptides

Junko Ishizaki[a], Yoshihiro Waki[b], Tatsuo Takahashi-Nishioka[c], Koichi Yokogawa[d], Ken-ichi Miyamoto[d,*]

[a]Department of Clinical Drug Informatics, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa 920-1192, Japan

[b]Department of Pharmacology, Nihon Pharmaceutical University, Saitama 362-0806, Japan

[c]Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa 920-1181, Japan

[d]Department of Hospital Pharmacy and Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8641, Japan

* Corresponding author: Department of Medicinal Informatics, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8641, Japan. Tel: +81-76-265-2045; Fax: +81-76-234-4280;

E-mail addresses: junishi@kenroku.kanazawa-u.ac.jp (J. Ishizaki), waki@nichiyaku.ac.jp (Y. Waki), t-takahashi@hokuriku-u.ac.jp (T. Takahashi), yokogawa@kenroku.kanazawa-u.ac.jp (K. Yokogawa), miyaken@kenroku.kanazawa-u.ac.jp (K. Miyamoto)

Key words: drug delivery, acidic oligopeptide, estradiol, levofloxacin, tissue-non-specific alkaline phosphatase.

Introduction

Bone is susceptible to a range of diseases, like other tissues. However, it is generally difficult to deliver and retain drugs in the bone. Bone is composed unique materials such as the inorganic compound hydroxyapatite (HAP) and bone-matrix proteins, which are quite different from the components of other tissues. Among them, HAP may be a promising target for selective drug delivery to bone.

The structures of several bone non-collagenous proteins that bind to HAP have a repeating sequence of acidic amino acids (Asp, Glu), which may serve as a HAP binding site. Osteopontin and bone sialoprotein, two major non-collagenous proteins in bone, have L-Asp and L-Glu repetitive sequences, respectively (Fig. 1), and rapidly bind to HAP after they are secreted in osteoblastic cell culture [1-3]. Thus, these acidic oligopeptides are candidate bone-targeting carriers. It was hypothesized that, after systemic administration, a drug tagged with such an oligopeptide would be selectively delivered and bind to bone, where the active drug would be released gradually during bone remodeling processes.

This review describes the properties of acidic oligopeptides and introduces the tagging of three model drugs, estradiol, quinolone antibiotics, and tissue-non-specific alkaline phosphatase (TNSALP), with an acidic oligopeptide to examine the clinical feasibility of the acidic oligopeptide strategy for selective drug delivery to bone.

Bioproperties of acidic oligopeptides

Homo-oligopeptides consisting of two to ten acidic amino acid residues, conjugated with 9-fluorenylmethylchloroformate (Fmoc) or fluorescein (FITC), were synthesized by routine solid-phase methods (Fig. 2). The dissociation constant (K_d) decreased with increasing numbers of acidic amino acid residues, and the binding rate (B_{max}) reached almost maximum at a length of six residues. The affinity for HAP was not related to the optical isomeric form (L or D) or the acidic amino acid species (Asp or Glu) [4]. When intravenously administered, fluorescein-labeled L-Asp hexapeptide (FITC-D_6) disappeared from the plasma with a biological half-life of 60 min, and 95% of the administered FITC was excreted within 24 h. However, FITC-D_6 rapidly bound to the bone and teeth and was detectable in bone tissues even at 14 d after administration (Fig. 3), but it was undetectable in other tissues [5]. Among the isomeric forms of the amino acids, the retention time was much longer for D-amino acid oligopeptides than for L-peptides. However, the L-amino acid (Asp) hexapeptide was chosen, because the D-peptide may be insensitive to hydrolysis in bone thus would not release the tagged drug.

Oligopeptide-tagged estradiol for osteoporosis

Osteoporosis is a serious problem for postmenopausal and aged women, and estrogen deficiency plays a causative role in its development. Estrogen can act directly or indirectly on osteoblasts and osteoclasts through estrogen receptor-mediated mechanisms [6-10], resulting in an anabolic effect on bone formation in estrogen-deficient animal models [11, 12]. Estrogen replacement therapy is an effective treatment in postmenopausal women to prevent reduction of

bone mineral density [13]. However, systemically administered estrogen is widely distributed to tissues other than bone, and prolonged therapy may increase the risks of endometritis, breast and endometrial cancer, and intrauterine hemorrhage [14, 15]. The development of osteoporosis therapies that are more efficient and selective for bone is desirable to avoid such adverse reactions.

Estradiol (E_2) was tagged with the L-Asp hexapeptide at the 3-position (E_2-3D_6) or the 17β-position (E_2-17βD_6) via a succinate ester (Fig. 4), and the pharmacokinetics and anti-osteoporotic effects of these compounds were examined [4, 16]. First, the binding affinities of these compounds at human estrogen receptors, ERα and ERβ, were tested *in vitro*. The affinities of E_2-3D_6 and E_2-17βD_6 to both estrogen receptors were about 100-fold and 10,000-fold, respectively, less than those of estradiol. Moreover, it is unlikely that the tagged estradiols can permeate through the plasma membrane, because of their hydrophilicity and large molecular size, and it seems probable that hydrolysis of the ester bond between estradiol and the L-Asp hexapeptide portion would be required for the tagged estradiols to show biological activity. At 6 h after a single intravenous administration (3.7 μmol/kg), the plasma concentration of the compound was very low, and the apparent tissue-to-plasma concentration ratio was almost 1.0 in most tissues and organs, indicating that the compound could not distribute or accumulate in tissues. Among the tissues examined, untagged estradiol was most highly distributed in the uterus, where it might cause adverse effects such as endometritis, whereas the accumulation of the tagged estradiols in the uterus was clearly lower. On the other hand, tagged estradiol was distributed to bone at 50-fold the level of untagged estradiol. Moreover, the level of tagged estradiol in bone decreased very

slowly, falling to basal level (10.5 ± 3.3 pmol/g) by 7 days, whereas untagged estradiol declined to the basal range within 1 day after injection.

It is well known that estradiol with a mono- or di-ester at position 3 or/and 17 shows prolonged estrogenic effects in the body due to the biological stability of esterified estradiol [17, 18]. This is so because removal of the ester is necessary for further metabolism and excretion of estradiol, and the de-esterification step appears to be the rate-limiting process in the elimination [19]. Indeed, at 6 h after the injection of untagged estradiol, the plasma concentration of estradiol had decreased almost to the basal level (7.6 ± 1.9 pmol/mL), whereas the tagged estradiols remained in the circulation at 6 h (E_2-$3D_6$; 26.7 ± 9.0 pmol/mL, E_2-$17\beta D_6$; 22.0 ± 12.0 pmol/mL, respectively). The lower total body clearance (CL_{tot}) of the tagged estradiols, compared with that of untagged estradiol, may result from superior biological stability. This would be favorable for the long-term action of tagged estradiol in bone.

When tagged estradiol (0.11, 0.37, or 1.1 μmol/kg, every seventh day) or untagged estradiol (0.37 μmol/kg, every third day) was intravenously administered into ovariectomized (OVX) mice for 28 days, the tagged estradiol dose-dependently reversed the decreased bone mineral density (BMD), and the estrogenic effects were selective to bone. The untagged estradiol increased not only the BMD but also the weights of the uterus and liver [4, 16]. Estradiol caused hypertrophy of uterine tissues and fatty degeneration in the liver. These results indicate that tagged estradiol reduced the risk of systemic adverse effects of estradiol, while retaining the osteogenic effect in bone.

The retention of E_2-$3D_6$ in the blood circulation and bone and its anti-osteoporotic effects were greater than those of E_2-$17\beta D_6$. The difference may be attributable to the greater stability of E_2-$3D_6$ to hydrolysis, compared with E_2-$17\beta D_6$, so that the retention in bone is longer for E_2-$3D_6$ than for E_2-$17\beta D_6$. It is likely that the tagged estradiols bound to bone are gradually hydrolyzed on the bone surface, possibly by peptidases, acid secreted by osteoclasts, and/or non-specific esterases, and that the released estradiol then acts via estrogen receptors.

Thus, these acidic oligopeptide-tagged estradiols, E_2-$3D_6$ and E_2-$17\beta D_6$, are promising candidates for the treatment of postmenopausal osteoporosis. The prolonged effect and selective delivery to bone should extend the medication interval and reduce the adverse effects of estradiol. However, when considering the clinical use of these oligopeptide-tagged estradiols, intravenous injection is undesirable because of the potential for poor compliance. The bioavailability of E_2-$17\beta D_6$ after oral administration was less than 10%. Therefore, Yokogawa et al. have developed an intranasal preparation to increase the bioavailability of the tagged molecules [20]. The bioavailability of E_2-$17\beta D_6$ after intranasal administration was increased to 75% by incorporating 2,6-di-*O*-methyl-β-cyclodextrin into the formulation, thereby creating an inclusion complex with E_2-$17\beta D_6$ that could achieve prolonged residence in the nasal cavity. The acidic oligopeptide-tagged estrogen provided increased medication compliance because of its long-acting and easy administration, and it increased anti-osteoporotic efficacy because of selective delivery to bone and reduced adverse effects of estradiol, resulting in improved quality of life for patients.

Oligopeptide-tagged quinolone antibiotics for osteomyelitis

Osteomyelitis is a progressive infectious process resulting in inflammatory destruction of bone, bone necrosis, and new bone formation. Chronic osteomyelitis is generally treated with surgical debridement, following the administration of parenteral antibiotics such as β-lactams or aminoglycosides. Without adequate debridement, most antibiotic regimens fail, regardless of the duration of therapy. Even when all necrotic tissue has been removed, the remaining bed of tissue must be considered as contaminated with the responsible pathogens. Thus, it is recommended to treat the patient with antibiotics for at least 4 weeks [21-23]. Moreover, the serum bactericidal titer, which is defined as the maximal dilution of the patient's serum that is able to kill the infecting organism *in vitro*, should be 1:4 or greater for a cure [24]. Thus, high doses and long-term administration of antibiotics are required for the treatment of osteomyelitis, because the delivery of antibiotics to bone is difficult. As the fluoroquinolones have a broad spectrum of activity *in vitro*, including activity against Gram-negative organisms, *Staphylococcus aureus*, and *S. epidermidis* [25], improving their bone distribution should increase their therapeutic effectiveness.

Takahashi et al. have designed levofloxacin (LVFX) tagged with the L-Asp hexapeptide at position 3 in the pyridone carbonic acid moiety, an active center of the drug, via a glycolate ester, (LVFX-3D_6) and norfloxacin (NFLX) tagged with the L-Asp hexapeptide at position N7 in the piperazinyl group via a glycolate and succinate linker (NFLX-7D_6)(Fig. 5) [26]. The minimum inhibitory concentrations (MIC) for anti-microbial activity of LVFX-3D_6 and NFLX-7D_6 against *S.*

aureus in vitro were 100- and 60-fold less, respectively, than those of the respective untagged drugs. One reason for this may be the increased hydrophilicity, arising from the acidic oligopeptide tag. Fluoroquinolones act by inhibiting bacterial topoisomerase II, which is responsible for the replication of double-stranded DNA, and thus must cross the bacterial membrane to be effective [27, 28]. The marked reduction of the antimicrobial activity of tagged quinolones indicates that the release of the parent drug by hydrolysis was required for biological activity, as in the case of tagged estrogen.

The pharmacokinetic parameters of LVFX-$3D_6$ and NFLX-$7D_6$ after a single intravenous injection are shown in Table 1. The AUC value of each tagged drug was two-fold that of the respective parent drug. In contrast, the Vdss value was significantly less for the tagged drugs than for the parent drugs, indicating a low distribution of the tagged compounds into tissues. The biological half-life was not changed by conjugation. Although these fluoroquinolones themselves have some affinity for calcium or bone, the level of tagged drugs in bone was more than 100-fold that of the parent drugs for at least 7 days after injection. After injection of LVFX-$3D_6$, the resulting LVFX was detected in bone marrow at about 1% of the concentration of LVFX-$3D_6$ in bone and was continuously released for 7 days. It is known that fluoroquinolones show extensive tissue penetration, and as a result, can cause adverse effects in various tissues, including the cardiovascular system, central nervous system, skin, liver, musculoskeletal system, and kidneys [29, 30]. The risk of adverse events may be decreased by conjugation with an oligopeptide because of lower distribution into tissues due to the increased hydrophilicity.

The therapeutic effect of tagged drugs on osteomyelitis was evaluated using a murine model of osteomyelitis, which was prepared by inoculation of *S. aureus* into the tibia. The amount of *S. aureus* remaining in the tibia after a single intravenous injection of the drug (27.7 mmol/kg for LVFX and LVFX-$3D_6$; 31.3 mmol/kg for NLFX and NFLX-$7D_6$) was determined, but only a slight reduction in the number of *S. aureus* was observed after the administration of LVFX, and no effect was seen for NLFX and NFLX-$7D_6$. The anti-microbial effect of LVFX was temporary, and the number of *S. aureus* had recovered to the level of the untreated control group at 6 days after administration. On the other hand, LVFX-$3D_6$ suppressed the growth of *S. aureus* for at least 6 days, showing a prolonged effect. Nevertheless, the effect of LVFX-$3D_6$ was not sufficient to kill *S. aureus*, presumably because the LVFX concentration generated from LVFX-$3D_6$ in the bone was insufficient to kill *S. aureus*. Fluoroquinolones show a concentration-dependent killing effect for susceptible organisms, with higher concentrations of fluoroquinolones resulting in more complete killing [31, 32]. Thus, the hydrolytic rate of LVFX-$3D_6$ appears to be an important determinant of the maximal anti-microbial effect. NFLX-$7D_6$ did not release NFLX and did not show any effect. These findings emphasize the importance of ensuring an appropriate susceptibility of the acidic oligopeptide-tagged drug to biological hydrolysis. To improve the effectiveness of the tagged drug, further modification is required, possibly devising a linkage susceptible to osteoclast-derived acid, peptidase, or non-specific esterase.

Oligopeptide-tagged enzyme for deficiency of tissue-non-specific alkaline phosphatase

Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization and is caused by a deficiency in tissue-non-specific alkaline phosphatase (TNSALP). Despite the presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals**,** clinical manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization, manifesting as rickets in infants and children and osteomalacia in adults [33]. ALP functions as an inorganic pyrophosphatase in bone [34, 35]. Inorganic pyrophosphate (PP_i) itself impairs the growth of HAP crystals and acts as an inhibitor of mineralization [36-39]. With insufficient TNSALP activity, PP_i is not adequately hydrolyzed, and the resulting build-up of unhydrolyzed PP_i in the perivesicular matrix inhibits the proliferation of pre-formed HAP crystals beyond the protective confines of matrix vesicle (MV) membranes.

Hypophosphatasia is caused by the deficiency of a single enzyme, TNSALP, making the disorder potentially amenable to enzyme replacement therapy (ERT). However, the results of ERT with intravenous infusion of plasma ALP or purified liver ALP in patients with hypophosphatasia have been disappointing [40-44]. Recently, one report has suggested that continuous delivery of a high dose of TNSALP to bone would be needed to induce physiological bone mineralization [45]. These observations suggest that the ALP enzymes administered intravenously were mostly consumed in the visceral organs and thus were not actually delivered to the bone at the physiological levels necessary to rescue the lesions. Therefore, it was tried to develop TNSALP targeted to bone by acidic oligopeptide.

The cDNAs were designed for two enzymes: anchorless recombinant human TNSALP

(rhTNSALP) and anchorless human TNSALP tagged with a stretch of six L-Asp residues at the C terminus (CD_6-TNSALP) (Fig. 6) [46]. When these cDNAs were transfected into Chinese hamster ovary (CHO-K1) cells, the enzymes were secreted from the cells into the culture medium, because they do not have the glycosylphosphatidylinositol anchoring signal peptide sequence from the C-terminus of human TNSALP cDNA. There was no significant difference in specific activity, Michaelis constant, or k_{cat} between the two enzymes. Thus, CD_6-TNSALP can restore mineralization in hypophosphatasia patients. Indeed, in cultures of hypophosphatasia patient-derived bone marrow cells, the tagged enzyme markedly improved mineralization, similar to the untagged enzyme rhTNSALP. Although PP_i completely inhibited the mineralization, even in the presence of P_i, the addition of CD_6-TNSALP restored the mineralization level to that of the PP_i-free control culture, as did TNSALP. Consequently, it seems that both the tagged and untagged enzymes may be taken up without modification into osteoblastic cells, possibly by endocytosis, and that both show similar bioactivity in terms of mineralization, by degrading PP_i in the cells.

To evaluate the pharmacokinetic tissue distribution of the enzymes, fluorescently labeled enzymes were prepared with the Alexa dye. CD_6-TNSALP showed about a 2-4-fold increase in bone retention, compared with untagged TNSALP, for at least 7 days after intravenous injection. The distribution to other tissues was not significantly different between the two enzymes, although the half-lives in the circulation were slightly different (rhTNSALP, 19.1 h; CD_6-TNSALP, 14.4 h) after a single intravenous injection. The different half-lives in the circulation may have been due

to the different carbohydrate structures, i.e., the tagged enzyme was less sialylated than the untagged enzyme, based on the result of lectin affinity chromatography [46]. It is known that higher sialic acid residue content at the terminus of the carbohydrate chain contributes to a longer half-life of ALP in the blood [47, 48].

These results demonstrate that the bone-targeting system using an acidic oligopeptide is also applicable to a large molecule such as an enzyme and suggest the possible clinical application of ERT for hypophosphatasia, although further studies are needed to confirm *in vivo* and clinical effectiveness of the tagged enzyme.

In conclusion, the cumulative results of the studies on acidic oligopeptide conjugation indicate a promising method of selectively delivering drugs to bone. Owing to the apparently strong affinity of acidic oligopeptides for HAP, the targeting system may be widely applicable for both small molecule drugs and large molecules as proteins in several bone diseases.

The presence of an acidic oligopeptide tag altered the drug's pharmacokinetic and biological properties, including blood clearance, distribution to visceral organs, and biological activity. The increased hydrophilicity created by the tag is thought to be responsible for these alterations. In considering clinical use, it is unlikely that tagged molecules would be suitable for oral administration because of their high hydrophilicity and their susceptibility to peptidases and esterases in the gastrointestinal tract. Other routes of administration, such as the intranasal route, may increase the bioavailability of tagged molecules, and the greater convenience may improve compliance and patient quality of life.

References

1. Oldberg A, Franzén A, Heinegård D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83: 8819-8823
2. Nagata T, Bellows CG, Kasugai S, Butler WT, Sodek J (1991) Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture. Biochem J 274: 513-520
3. Kasugai S, Nagata T, Sodek J (1992) Temporal studies on the tissue compartmentalization of bone sialoprotein (BSP), osteopontin (OPN), and SPARC protein during bone formation in vitro. J Cell Physiol 152: 467-477
4. Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M, Sawanishi H, Morito K, Masamune Y, Kasugai S, Yokogawa K, Miyamoto K (2001) Novel drug delivery system to bone using acidic oligopeptide; pharmacokinetic characteristics and pharmacological potential. J Drug Target 9: 111-121
5. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K (2000) Selective drug delivery system to bone; small peptide (Asp)6 conjugation. J Bone Miner Re 15: 936-943
6. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241: 81-84

7. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84-86
8. Oursler MJ, Osdoby P, Pyfferoen J, Riggs BL, Spelsberg TC (1991) Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88: 6613-6617
9. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T (1997) Expression of estrogen receptor beta in rat bone. Endocrinology 138: 4509-4512
10. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Löwik CW, Pols HA, van Leeuwen JP (1997) Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology 138: 5067-5070
11. Bain SD, Bailey MC, Edwards MW (1992) The anabolic effect of estrogen on endosteal bone formation in the mouse is attenuated by ovariohysterectomy; a role for the uterus in the skeletal response to estrogen? Calcif Tissue Int 51: 223-228
12. Wronski TJ, Yen CF, Qi H, Dann LM (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132: 823-831
13. Lindsay R, Tohme JF (1990) Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295
14. Astedt B (1981) On the role of estrogens in endometrial carcinogenesis. Acta Obstet Gynecol Scand 106(Supple): 33-35
15. Gambrell RD (1982) The menopause; benefits and risks of estrogen-progestogen

replacement therapy. Fertil Steril 37: 457-474

16. Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, Morito K, Masamune Y, Waki Y, Kasugai S, Miyamoto K (2001) Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142: 1228-1233
17. Larner JM, MacLusky NJ, Hochberg RB (1985) The naturally occurring C-17 fatty acid esters of estradiol are long-acting estrogens. J Steroid Biochem 22: 407-413
18. Larner JM, Hochberg RB (1985) The clearance and metabolism of estradiol and estradiol-17-esters in the rat. Endocrinology 117: 1209-1214
19. Hershcopf RJ, Bradlow HL, Fishman J, Swaneck GE, Larner JM, Hochberg RB (1985) Metabolism of estradiol fatty acid esters in man. J Clin Endocrinol Metab 61: 1071-1075
20. Yokogawa K, Toshima K, Yamoto K, Nishioka T, Sakura N, Miyamoto K (2006) Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol. Biol Pharm Bull 29: 1229-1233
21. Dirschl DR, Almekinders LC (1993) Osteomyelitis. Common causes and treatment recommendations. Drugs 45: 29-43
22. Mader JT, Ortiz M, Calhoun JH (1996) Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 13: 701-724
23. Mader JT, Mohan D, Calhoun J (1997) A practical guide to the diagnosis and management of bone and joint infections. Drugs 54: 253-264
24. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB (1987) Multicenter

collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 83: 218-222

25. Mader JT, Cantrell JS, Calhoun J (1990) Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 72: 104-110.
26. Takahashi TN, Kobayashi S, Miyamoto K (2008) Bone targeting of quinolone antibiotics conjugated with an acidic oligopeptide. Pharm Res (In press)
27. Lewis RJ, Tsai FT, Wigley DB (1996) Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays 18: 661-67.
28. Shen LL, Chu DTW (1996) Type II DNA topoisomerases as antibacterial targets. Curr Pharm Des 2: 195-208
29. Blondeau JM (1999) Expanded activity and utility of the new fluoroquinolones; a review. Clin Ther 21: 3-40
30. O'Donnell JA, Gelone SP (2000) Fluoroquinolones. Infect. Dis Clin North Am 14: 489-513
31. Blaser J, Stone BB, Groner MC, Zinner SH (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31: 1054-1060
32. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M (1998) Pharmacodynamics of levofloxacin; a new paradigm for early clinical

trials. JAMA 279: 125-129

33. Whyte MP (2001) Hypophosphatasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 8th Ed. McGraw-Hill, New York, pp 5313-5329
34. Moss DW, Eaton RH, Smith JK, Whitby LG (1967) Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 102: 53-57
35. Leone FA, Rezende LA, Ciancaglini P, Pizauro JM (1998) Allosteric modulation of pyrophosphatase activity of rat osseous plate alkaline phosphatase by magnesium ions. Int J Biochem Cell Biol 30: 89-97
36. Anderson HC (1988) Mechanisms of pathologic calcification. Rheum Dis Clin North Am 14: 303-319
37. Fleisch H, Russell RG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901-903
38. de Jong AS, Hak TJ, van Duijn P (1980) The dynamics of calcium phosphate precipitation studied with a new polyacrylamide steady state matrix-model; influence of pyrophosphate collagen and chondroitin sulfate. Connect Tissue Res 7: 73-79
39. Meyer JL (1984) Can biological calcification occur in the presence of pyrophosphate? Arch Biochem Biophys 231: 1-8
40. Whyte MP, Valdes R, Ryan LM, McAlister WH (1982) Infantile hypophosphatasia; enzyme

replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. J Pediatr 101: 379-386

41. Whyte MP, McAlister WH, Patton LS, Magill HL, Fallon MD, Lorentz WB, Herrod HG (1984) Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma; results in three additional patients. J Pediatr 105: 926-933
42. Whyte MP, Magill HL, Fallon MD, Herrod HG (1986) Infantile hypophosphatasia; normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase. J Pediatr 108: 82-88
43. Weninger M, Stinson RA, Plenk H, Böck P, Pollak A (1989) Biochemical and morphological effects of human hepatic alkaline phosphatase in a neonate with hypophosphatasia. Acta Paediatr Scand 360: 154-160
44. Whyte MP, Landt M, Ryan LM, Mulivor RA, Henthorn PS, Fedde KN, Mahuren JD, Coburn SP (1995) Alkaline phosphatase; placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest 95: 1440-1445
45. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM

mineralization to bone. Genes Dev 19: 1093-1104

46. Nishioka T, Tomatsu S, Gutierrez MA, Miyamoto K, Trandafirescu GG, Lopez PL, Grubb JH, Kanai R, Kobayashi H, Yamaguchi S, Gottesman GS, Cahill R, Noguchi A, Sly WS (2006) Enhancement of drug delivery to bone; characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 88: 244-255
47. Walton RJ, Preston CJ, Russell RG, Kanis JA (1975) An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease. Clin Chim Acta 63: 227-229
48. Komoda T, Sakagishi Y (1987) The function of carbohydrate moiety and alteration of carbohydrate composition in human alkaline phosphatase isoenzymes. Biochim Biophys Acta, 523: 395-406

Figure

Fig. 1. Amino acid sequences of bone matrix proteins

Bone sialoprotein

MKTALILLSILGMACAFSMKNLHRRVKI**ED**S**EE**NGVFKYRPRYYLYKHAYFYPHLKRFPVQGSS**D**
SS**EE**NG**DD**SS**EEEEEEEE**TSN**E**G**E**NN**EE**SN**EDED**S**E**A**E**NTTLSATTLGYG**ED**ATPGTGYTGLAAI
QLPKKAG**D**ITNKATK**E**K**E**S**DEEEEEEEE**GN**E**N**EE**S**E**A**E**V**DE**N**E**QGINGTSTNST**E**A**E**NGNGSSG**E**
DNG**EE**G**EEE**SVTGANA**E**GTT**E**TGGQGKGTSKTTTSPNGGF**E**PTTPPQVYRTTSPPFGKTTTV**E**Y**E**
G**E**Y**E**YTGAN**D**Y**D**NGY**E**IY**E**S**E**NG**E**PRG**D**NYRAY**EDE**YSYFKGQGY**D**GY**D**GQNYYHHQ

Osteopontin

MRIAVICFCLLGITCAIPVKQA**D**SGSS**EE**KQLYNKYP**D**AVATWLNP**D**PSQKQNLLAPQTLPSKSN
ESH**D**HM**DD**M**DDEDDDD**HV**D**SQ**D**SI**D**SN**D**S**DD**V**DD**T**DD**SHQS**DE**SHHS**DE**S**DE**LVT**D**FPT**D**LPAT**E**
VFTPVVPTV**D**TY**D**GRG**D**SVVYGLRSKSKKFRRP**D**IQYP**D**AT**DED**ITSHM**E**S**EE**LNGAYKAIPVAQ
DLNAPS**D**W**D**SRGK**D**SY**E**TSQL**DD**QSA**E**THSHKQSRLYKRKAN**DE**SN**E**HS**D**VI**D**SQ**E**LSKVSR**E**FH
SH**E**FHSH**ED**MLVV**D**PKSK**EED**KHLKFRISH**E**L**D**SASS**E**VN

Acidic amino acids are emphasized.

Fig. 2. Structure of FITC-D_6



Fig. 3. Confocal laser scanning microscopic images of bones



Ground sections of bones were prepared from rats 24 h after injection with FITC-D_6.

Fig. 4. Structures of E_2-3D_6 and E_2-17βD_6



E_2-17βD_6



E_2-3D_6

Fig. 5. Structures of NFLX-7D$_6$ and LVFX-3D$_6$



NFLX-7D$_6$



LVFX-3D$_6$

Table 1. Pharmacokinetic parameters after an intravenous administration of fluoroquinolones and their Asp-oligopeptide tagged drugs

	LVFX (27.7 μmol/kg)	LVFX-3D$_6$ (27.7 μmol/kg)	NFLX (31.3 μmol/kg)	NFLX-7D$_6$ (31.3 μmol/kg)
$AUC_{0\text{-}2\ h}$ (nmol/mL·h)	8.77 ± 0.39	24.8 ± 0.8*	9.66 ± 1.70	20.7 ± 7.8*
Vd_{ss} (L/kg)	1.55 ± 0.04	0.27 ± 0.06*	1.86 ± 0.35	0.63 ± 0.14*
$t_{1/2}$ (h)	0.49 ± 0.09	0.38 ± 0.02	0.52 ± 0.09	0.62 ± 0.17

Each compound was injected into the jugular vein of mice at the indicated dose. Each value represents the mean ± S.D. (n = 4).

*Significantly different from the parent drug at $p < 0.05$.

Fig. 6. Structures of CD_6-TNSALP

Anchor-intact TNSALP



Anchorless TNSALP



Anchorless CD_6-TNSALP